PROCEPT BioRobotics 2025 Q2 Earnings Improved Losses Amid Revenue Surge

PROCEPT BioRobotics reported mixed results for Q2 2025, showing improved losses and robust revenue growth. The company’s total revenue rose 48.4% to $79.18 million, and it narrowed its per-share loss and net loss year-over-year. However, the business continues to operate at a loss for the fifth consecutive quarter, while the stock has seen sharp declines across timeframes. The company raised its full-year revenue guidance, signaling optimism for the remainder of the year.

Revenue
Revenue saw a significant 48.4% year-over-year increase, reaching $79.18 million in Q2 2025. This growth was driven by strong performance across all business segments. System sales and rentals contributed $25.03 million, providing a foundational boost to the company’s top line. Handpieces and other consumables generated the largest share of revenue at $49.13 million, reflecting continued demand for its surgical tools. Meanwhile, service revenue added $5.02 million, highlighting the ongoing importance of recurring income streams. Collectively, these segments propelled the company’s revenue growth, indicating expanding adoption and usage of its Aquablation therapy.

Earnings/Net Income
PROCEPT BioRobotics narrowed its losses in Q2 2025, with a per-share loss of $0.35, compared to $0.50 in the prior-year period, representing a 30.0% improvement. On a net basis, the company reduced its loss to $19.58 million, down 23.6% from $25.63 million in Q2 2024. Despite these improvements, the company remains unprofitable, having posted losses for five consecutive years in the same period. These results suggest that while cost management is showing progress, the path to profitability remains long.

Price Action
The stock price of PROCEPT BioRobotics continued to face downward pressure, with a 5.74% decline in the latest trading day and an 18.39% drop over the past full trading week. The month-to-date loss stood at 31.64%, reflecting ongoing investor concerns about the company’s financial performance and future prospects.

Post-Earnings Price Action Review
Following the earnings release, a strategy of buying PRCT shares after a positive earnings beat and selling after 30 days yielded a poor -3.18% return, significantly underperforming the benchmark return of 38.70%. The approach showed a maximum drawdown of 0.00% and a negative Sharpe ratio of -0.01, underscoring the low profitability and high volatility of the stock. With a volatility rate of 64.53%, the holding period was marked by significant price swings, suggesting market uncertainty.

CEO Commentary
Reza Zadno, CEO of PROCEPT BioRobotics, emphasized the company’s strong second-quarter performance, driven by global demand and procedural momentum. Strategic priorities include expanding Aquablation therapy utilization in the U.S., deepening hospital market penetration for benign prostatic hyperplasia (BPH), accelerating enrollment in the WATER IV prostate cancer study, and advancing international commercial efforts. Zadno expressed confidence that these initiatives will position the company for sustained growth and long-term value creation.

Guidance
The company raised its 2025 total revenue guidance to $325.5 million, up from the previous $323.0 million, indicating a more optimistic outlook for the year. PROCEPT BioRobotics expects a gross margin of approximately 64.5%, with potential headwinds of $1.0–$2.0 million if global tariff rates remain unchanged. Operating expenses are projected at $302.0 million, in line with prior guidance, while the company anticipates a 2025 Adjusted EBITDA loss of around $35.0 million.

Additional News
In non-earnings related news,哔哩哔哩, a leading Chinese online entertainment and community platform, featured a detailed analysis of the game demo for *The Crowd* and the character song of Qin Xiaonan. The article highlighted the depth of game design and the nuances embedded in the demo. While not directly related to PROCEPT BioRobotics, this news reflects broader trends in digital content creation and audience engagement. Such developments underscore the growing intersection of technology and entertainment, where immersive experiences are increasingly shaped by creative storytelling and interactive elements.